Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rani Therapeutics Holdings Inc (RANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: RANI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.97% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 119.71M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 4 | Beta -0.01 | 52 Weeks Range 0.39 - 2.82 | Updated Date 10/20/2025 |
52 Weeks Range 0.39 - 2.82 | Updated Date 10/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3796.75% |
Management Effectiveness
Return on Assets (TTM) -93.94% | Return on Equity (TTM) -1187.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35589605 | Price to Sales(TTM) 99.76 |
Enterprise Value 35589605 | Price to Sales(TTM) 99.76 | ||
Enterprise Value to Revenue 29.66 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 47898228 | Shares Floating 33616892 |
Shares Outstanding 47898228 | Shares Floating 33616892 | ||
Percent Insiders 19.54 | Percent Institutions 17.04 |
Upturn AI SWOT
Rani Therapeutics Holdings Inc
Company Overview
History and Background
Rani Therapeutics was founded in 2012. The company focuses on developing a novel oral biologics delivery platform called the RaniPill capsule. It has achieved milestones in preclinical and clinical trials, advancing its technology towards commercialization.
Core Business Areas
- Oral Biologics Delivery: Rani Therapeutics' core business is the development and commercialization of the RaniPill capsule, a platform technology designed for oral delivery of biologics (proteins, peptides, and antibodies). The RaniPill capsule autonomously injects drugs into the small intestine.
Leadership and Structure
Rani Therapeutics is led by a management team with experience in pharmaceuticals and drug delivery. The organizational structure consists of research and development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- RaniPill Capsule: The RaniPill capsule is Rani Therapeutics' main product, an oral delivery platform for biologics. It is currently in clinical trials for various indications. As it is not commercialized market share is not applicable yet. Competitors include companies developing alternative drug delivery methods, such as subcutaneous injections and other oral biologics delivery platforms. The overall market is dominated by injectable biologics.
Market Dynamics
Industry Overview
The pharmaceutical industry is witnessing growing demand for biologics, but their delivery is often limited to injections. The oral biologics market is an emerging area with the potential to disrupt traditional delivery methods.
Positioning
Rani Therapeutics aims to position itself as a leader in oral biologics delivery with the RaniPill capsule, offering a patient-friendly alternative to injections. Their competitive advantage lies in their unique technology and potential to expand the reach of biologics.
Total Addressable Market (TAM)
The TAM for oral biologics is estimated to be in the tens of billions of dollars, encompassing a significant portion of the overall biologics market. Rani Therapeutics is positioned to capture a share of this market by offering an alternative to injections.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology (RaniPill)
- Potential for improved patient compliance
- Reduced need for healthcare professional administration
Weaknesses
- Technology is still in clinical development
- Regulatory hurdles for approval
- Limited clinical data compared to established delivery methods
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Potential for licensing or acquisition
Threats
- Competition from established injectable biologics
- Failure to achieve positive clinical trial results
- Regulatory setbacks
Competitors and Market Share
Key Competitors
- VTVT
- NVO
- SNY
Competitive Landscape
Rani Therapeutics' competitive advantage lies in its novel oral delivery platform. However, it faces competition from established pharmaceutical companies with existing injectable biologics. The market share is currently dominated by companies with approved injectable biologic products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of the RaniPill capsule. Analyst estimates vary based on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding the intellectual property portfolio.
Summary
Rani Therapeutics is a development-stage company with a promising oral biologics delivery platform, the RaniPill capsule. The company's success hinges on positive clinical trial results and regulatory approval. It faces competition from established pharmaceutical companies and potential setbacks in clinical development. Rani needs to achieve clinical and regulatory success to capitalize on the market opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rani Therapeutics' SEC filings
- Company website
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.ranitherapeutics.com |
Full time employees 105 | Website https://www.ranitherapeutics.com | ||
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.